Long-term efficacy of intracoronary stem cells transplantation in patients with acute myocardial infarction

Abstract

Abstract: AIM: To investigate the security as well as the improvement of cardiac function in patients with acute myocardial infarction who ac-cepted intracoronary transplantation of autologous bone marrow mesenchymal stem cells (MSCs),and to discuss the possible mechanism. METHODS: 20 cases of acute myocardial infarction patients after percutaneous coronary intervention (PCI) received intracoronary transplantation of MSCs. (treatment group). Another 20 patients who refused stem-cell therapy after PCI served as control (conrol group). All patients underwent clinical evaluation, 2D/TDI echocardiogram, and ¹⁸F-FDG-SPECT at 1 week/1 year after PCI.RESULTS: Body temperature elevation or malignant arrhythmia associated with transplantation was not found in treatment group. Compared with the control group, echocardiographic systolic and diastolic function parameters and SPECT metabolic defects indicators were improved significantly in treatment group 1 year after PCI,there were statistical differences(P<0.05).CONCLUSION: Intracoronary transplantation of MSCs is safe and effective, and may significantly improve long-term cardiac performance. MSCs-associated myocardial regeneration and neovascularization may be the possible mechanisms.

Key words: Myocardial infarction, Therapy, Bone marrow transplantation, Autologous, Anagenesis

CLC Number:

R541

ZHU Lin-lin, XIE Xiang-rong, ZHANG Juan, SHAN Shou-jie , CHEN Shao-liang. Long-term efficacy of intracoronary stem cells transplantation in patients with acute myocardial infarction[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 674-679.

References

[1] Obeid M, Saber Sel D, Ismael Ael D,et al. Mesenchymal stem cells promote hard-tissue repair after direct pulp capping[J]. J Endod, 2013, 39(5):626-631.
[2] Yang Z, Zhang F, Ma W, et al. A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery[J].Cardiovasc Ther, 2010,28(6):380-385.
[3] Ouyang H, Zhang JB, Liu Y, et al. Research on application of modified polyethylene glycol hydrogels in the construction of tissue engineered heart valve[J].Zhonghua Wai Ke Za Zhi, 2008,46(22): 1723-1726.
[4] Soejitno A, Wihandani DM, Kuswardhani RA. Clinical applications of stem cell therapy for regenerating the heart[J].Acta Med Indones, 2010, 42(4): 243-257.
[5] Tomita S, Li RK, Weisel R, et al. Autologous transplantation of bone marrow cells improves damaged heart function[J]. Circulation,1999,100 (suppl Ⅱ): Ⅱ-247-256.
[6] Orlic D, Kajstura J, Chimenti S, et al .Mobilized bone marrow cells repair the infracted heart, improving function and survival[J]. Proc Natl Acad Sci USA,2001,98(18):10344-10349.
[7] Chen M, Fan ZC, Liu XJ, et al. Effects of autologous stem cell transplantation on ventricular electrophysiology in doxorubicin-induced heart failure[J]. Cell Biol Int, 2006,30(7):576-582.
[8] Wang Y, Zhang G, Hou Y, et al. Transplantation of microencapsulated Schwann cells and mesenchymal stem cells augment angiogenesis and improve heart function[J]. Mol Cell Biochem, 2012,366 (1/2): 139-147.
[9] Qian HY, Yang YJ, Huang J, et al. Effects of Tongxinluo-facilitated cellular cardiomyoplasty with autologous bone marrow-mesenchymal stem cells on postinfarct swine hearts[J]. Chin Med J (Enl), 2007, 120(16):1416-1425.
[10]Otto Beitnes J, Oie E, Shahdadfar A, et al. Intramyocardial injections of human mesenchymal stem cells following acute myocardial infarction modulate scar formation and improve left ventricular function[J]. Cell Transplant,2012,21(8):1697-1709.
[11]Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction[J].Am J Cardiol, 2004,94(1): 92-95.
[12]单守杰, 陈绍良,刘煜昊,等. 自体骨髓间质干细胞移植对梗死心肌的修复作用[J].中国临床康复,2005, 9(7): 63-65.

[1]	WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu. Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
[2]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[3]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[4]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[5]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[6]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[7]	YU Qiaoling, ZHAI Weiwei, LIU Ping, QIU Bo, WU Huizhen. Research progress in plasma concentration monitoring of rivaroxaban [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 809-817.
[8]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[9]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[10]	QIAN Jin, WANG Fengyan. Influence factors of serum NT-proBNP level in elderly patients with acute myocardial infarction after PCI and its influence on short-term prognosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 658-665.
[11]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[12]	LI Yang, PAN Weizhong, ZHANG Xiaolu, YU Cuicui. Effects of recovered autologous blood transfusion on immune function and inflammatory response in patients with cesarean section [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 514-524.
[13]	CHEN Manxin, ZHANG Bingyu, DAI Min. Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
[14]	LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
[15]	LIU Tong, XU Jiaming, WANG Jinhuo, YIN Lei, CHEN Yongquan, GUO Jianrong. Changes of anesthetic drug concentration in plasma during isolation of autologous blood with acute isovolumic hemodilution and its influence on anesthetic effect after reinfusion [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 413-418.